Camille C. Lee

Camille C. Lee has extensive experience in the pharmaceutical industry spanning over several decades. Camille C. is currently serving as the SVP and US Head of Immunology at UCB since May 2019, where they oversee the patient value unit for Immunology in the US, including P&L, portfolio strategy, commercial and medical affairs execution, and talent development.

Prior to that, Camille held the role of SVP Alzheimer's Disease Therapeutic Area at Biogen from September 2017 to December 2018. In this position, they were responsible for the global Alzheimer's portfolio strategy, serving as the cross-functional project lead for a key asset in phase III and leading a global partnership with Eisai as the co-chair of the Joint Commercialization Committee.

Before joining Biogen, Camille had a long and successful career at Novo Nordisk. Their roles included Senior Vice President of Diabetes & Obesity Marketing from August 2006 to December 2016, where they played a pivotal role in growing diabetes net sales from $1 billion to $6.3 billion. Camille C. was also the Regional Business Director, Vice President of International Marketing, Marketing Director, Manager of Diabetes Product Launch Planning, Head of Competitor Intelligence, International Product Manager, Product Manager, and Sales Representative during their time at Novo Nordisk.

Overall, Camille C. Lee's work experience showcases their expertise in various areas of the pharmaceutical industry, including marketing, sales, strategic development, and leadership.

Camille C. Lee earned a Bachelor of Science (B.Sc.) in Marketing from California State University, Long Beach in the years 1984-1988. Camille C. also completed an Executive Leadership Program at The Wharton School in 2012, with a focus on Healthcare. In 2013, they attended the Harvard Business School Executive Education program and studied Strategic Leadership. Additionally, Camille pursued an E*MBA at the Copenhagen International Management Institute.